More News! 9 Jan 2018 Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […] January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 6 Jan 2018 A Self-Portrait of the Microbes that Live on our Skin Is a portrait fully complete without portraying the millions of bacteria that live on our skin? Mellissa Fisher makes them the focus of her self-portraits. British artist Mellissa Fisher creates quite unique portraits. The material for her face sculptures is agar rich in nutrients, the same one that scientists use to grow bacteria and fungi […] January 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Jan 2018 Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded by CD3 and Axxam, based in Leuven, Belgium, and Milan, Italy, respectively. Today, the biotech announced that it has completed a €15.2M Series A financing […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2017 Oxford Biotech Makes a Latin American Deal for Its Antibiotic In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […] December 21, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2017 Britain’s Life Science Strategy: What UK Biotech Can Do From the Bottom Up Britain has been making a concerted effort to grow its biotech sector, especially after Brexit. What’s the plan and what can UK biotech do? The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee twelve-year old, on a mission to push forward legislation to prevent […] December 21, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
More News! 18 Dec 2017 French Biotech will work with the World’s Leader in Hearing Implants Sensorion and Cochlear will explore if a combination of a drug and a hearing implant can improve the treatment of hearing loss. Based in the French city of Montpellier, Sensorion specializes in the development of treatments for inner ear disorders such as vertigo and hearing loss. The company’s technology received major recognition today with the […] December 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 14 Dec 2017 New Biotech in Oxford Takes on Arthritis of the Spine Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […] December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2017 PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody ChemomAb kicked off its antibody efforts as a company in 2011, and its $10M Series B has attracted none other than Peter Thiel. Israeli biotech has been attracting quite sizeable funds recently, largely those of UK investment outfit Arix Bioscience. Yesterday it was announced that Peter Theil, co-founder of PayPal and assassin of Gawker, led […] December 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
More News! 2 Dec 2017 Kunstformen der Natur: 19th Century Biology Art in Exhibition Kunstformen der Natur, by Ernst Haeckel, is a beautiful series of prints that have influenced scientists and artists alike. A Dutch exhibition shows them like never before. In the fashion of the 19th century, Ernst Haeckel was simultaneously a biologist, philosopher, physician, and artist. A Darwin contemporary, although Haeckel supported Lamarckist and other evolutionary theories that are […] December 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 30 Nov 2017 Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […] November 30, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 18 Nov 2017 Bacterial Art Starts a Debate on Money and International Borders We have been told over and over that bacteria are everywhere around us, especially on your smartphone screen. But most of us haven’t stopped to reflect on the fact — and consequences — of bacteria being all over our money. A scientific study by the New York University called the Dirty Money Project revealed in […] November 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2017 Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […] November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email